Baptist Health Hardin, Elizabethtown
Baptist Health Lexington, Lexington
University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06712316

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

University of Kentucky/Markey Cancer Center, Lexington

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06287775

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

CHI Saint Joseph Cancer Center - East, Lexington
University of Kentucky Chandler Medical Center, Lexington

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06119581

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
Commonwealth Cancer Center-Corbin, Corbin
Saint Elizabeth Healthcare Edgewood, Edgewood
at 5 pa

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Baptist Health Hardin Cancer Center, Elizabethtown

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06712355

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

University of Kentucky ( Site 0019), Lexington

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06731907

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Xencor Investigative Site, Louisville

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT05433142

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Norton Cancer Institute, Louisville

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT04198766

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT06060613

EXoPERT EMERALD Clinical Study

Lexington VA Healthcare System, Lexington
KCTL, Louisville

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 45 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT07186296

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

University of Louisville, Louisville

Nagre-recruitPhase 2

Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT04614103

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

University of Louisville, Louisville

Nagre-recruitPhase 1/2

Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT05361174

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

University of Kentucky/Markey Cancer Center, Lexington

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment

University of Kentucky, Lexington

Nagre-recruit

Edad 18 pataas · Lahat ng kasarian · Na-update May 8, 2026 · NCT06047301

A Study of ZW251 in Participants With Advanced Solid Tumors

Norton Cancer Institute, Louisville

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update May 7, 2026 · NCT07164313

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

University of Kentucky/Markey Cancer Center, Lexington

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

University of Kentucky/Markey Cancer Center, Lexington

Nagre-recruitPhase 2

18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688

Precision Lung Cancer Survivorship Care Intervention

Markey Cancer Center, Lexington

Nagre-recruit

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 23, 2026 · NCT05857995

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

University of Kentucky Markey Cancer Center, Lexington

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT06778863

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Baptist Corbin, Corbin
Baptist Hardin, Elizabethtown
Baptist Lexington, Lexington

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 40 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT05366881

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Lexington VA Health Care System, Lexington
Robley Rex VA Medical Center, Louisville

Nagre-recruitObservasyonal na pag-aaral

Edad 29 hanggang 85 · Lahat ng kasarian · Na-update Nob 13, 2024 · NCT06426628

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.